TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

BE PHARMS

Infectious DiseaseDermatologyCardiovascular
Generics

BE PHARMS is a generic drug manufacturer focused on Infectious Disease, Dermatology, Cardiovascular. Key products include DAPTOMYCIN.

2019
Since
9
Drugs
-
Trials
96
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2026-01-07
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2025-11-25
Labeling
NEOSTIGMINE METHYLSULFATE 2025-10-24
Labeling
PANTOPRAZOLE SODIUM 2025-10-15
Labeling
PANTOPRAZOLE SODIUM 2025-10-15
Labeling
PANTOPRAZOLE SODIUM 2025-10-01
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 25%
1 drugs
Dermatology 25%
1 drugs
Cardiovascular 25%
1 drugs
Respiratory 25%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Respiratory
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Dermatology, Respiratory
B BRAUN specialty
Infectious Disease, Dermatology, Cardiovascular
COSETTE other
Cardiovascular, Dermatology, Infectious Disease